PPAR-gamma agonists: shifting attention from the belly to the heart?
van Wijk
Jeroen P H
JP
Rabelink
Ton J
TJ
D017667:Adipocytes / Q000187:drug effects / Q000378:metabolism; D002316:Cardiotonic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D002340:Carotid Artery Diseases / Q000209:etiology / Q000517:prevention & control; D017536:Carotid Artery, Common / Q000187:drug effects / Q000473:pathology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D006801:Humans; D007333:Insulin Resistance; D024821:Metabolic Syndrome / Q000188:drug therapy*; D008954:Models, Biological; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists* / Q000502:physiology; D045162:Thiazolidinediones / Q000494:pharmacology* / Q000627:therapeutic use; D014157:Transcription Factors / Q000819:agonists* / Q000502:physiology
D002316:Cardiotonic Agents; D018160:Receptors, Cytoplasmic and Nuclear; D045162:Thiazolidinediones; D014157:Transcription Factors